p-AKT Expression on Clinical Outcomes in Malignant Lymphoma
The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study
1 other identifier
observational
262
1 country
1
Brief Summary
PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2012
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2013
CompletedFirst Submitted
Initial submission to the registry
February 7, 2013
CompletedFirst Posted
Study publicly available on registry
February 11, 2013
CompletedFebruary 11, 2013
February 1, 2013
2 months
February 7, 2013
February 7, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
Difference of overall survival according to p-AKT status in malignant lymphoma
study entry
Secondary Outcomes (1)
Subgroup analysis of overall survival according to histologic subtypes (GCB vs non GCB)
study entry
Other Outcomes (1)
Subgroup analysis of overall survival according to International Prognostic Index risk groups
study entry
Study Arms (1)
p-AKT
p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)
Interventions
p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
Eligibility Criteria
Patients with malignant lymphoma who are treated in a tertiary hospital in Korea (Samsung Medical Center)
You may qualify if:
- the patients were pathologically confirmed of malignant lymphoma, according to the World Health Organization classification;
- the patients had adequate paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT.
You may not qualify if:
- \. Primary central nervous system lymphoma was excluded in this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Samsung Medical Center
Seoul, South Korea
Related Publications (1)
Hong JY, Hong ME, Choi MK, Kim YS, Chang W, Maeng CH, Park S, Lee SJ, Do IG, Jo JS, Jung SH, Kim SJ, Ko YH, Kim WS. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases. Ann Oncol. 2014 Jan;25(1):182-8. doi: 10.1093/annonc/mdt530.
PMID: 24356628DERIVED
Biospecimen
paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Won Seog Kim, MD PhD
Samsung Medical Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
February 7, 2013
First Posted
February 11, 2013
Study Start
December 1, 2012
Primary Completion
February 1, 2013
Study Completion
February 1, 2013
Last Updated
February 11, 2013
Record last verified: 2013-02